NAFDAC Approves R21 Malaria Vaccine for Use in Nigeria
Following an initial regulatory process, NAFDAC says R21 is safe for use in Nigerian children from one year to three years, pending Phase 4 clinical trials. By Prof Mojisola Christianah …
NAFDAC Approves R21 Malaria Vaccine for Use in Nigeria Read More